News and Announcements
SUDA Granted Canadian Patent for SUD-002
- Published April 12, 2016 3:34PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
12th April 2016, ASX Announcement
SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug deliver, is pleased to announce that the Canadian Intellectual Property Office has issued Canada Patent number 2,673,049, covering the Company’s novel oral spray of ondansetron (SUD-002). The patent is entitled “Stable Anti-nausea Oral Spray Formulations and Methods” and has an expiry date of 21 December 2017.
This is the second patent to be issued in Canada for SUDA’s SUD-002 oral spray to treat nausea and vomiting induced by chemotherapy, radiotherapy and also in post-operative settings. It is part of the broad intellectual property portfolio acquired by SUDA from NovaDel in 2013. The patent has been granted or is pending in other major jurisdictions.
To view the full article please click on the button below.